ARTICLE
12 November 2024

Bipartisan AGs Reach $49 Million Settlement Over Alleged Price-Fixing In Generic Drugs Market

CO
Cozen O'Connor

Contributor

Founded in 1970, Cozen O’Connor has more than 925 attorneys practicing internationally in 32 cities across North America and Europe. We are a full-service firm with award-winning practices in litigation, business law, and government relations, and our attorneys have experience operating in all sectors of the economy. Our diverse client list includes global Fortune 500 companies, middle-market firms poised for growth, ambitious startups, and high-profile individuals.

A bipartisan coalition of 50 states, D.C., and two territories reached settlements with Heritage Pharmaceuticals, Inc. and Apotex Corp. to resolve allegations of price fixing generic drugs in violation of the Sherman Act.
United States Connecticut Food, Drugs, Healthcare, Life Sciences
Cozen O'Connor’s articles from Cozen O'Connor are most popular:
  • with readers working within the Retail & Leisure industries
Cozen O'Connor are most popular:
  • within Tax, Immigration and Insurance topic(s)
  • in United Kingdom
  • A bipartisan coalition of 50 states, D.C., and two territories reached settlements with Heritage Pharmaceuticals, Inc. and Apotex Corp. to resolve allegations of price fixing generic drugs in violation of the Sherman Act.
  • As part of complaints filed in 2017 and 2019, the AGs allege that the companies, along with other drug manufacturers and their executives, coordinated to inflate prices for multiple generic drugs used to treat a number of conditions, among other things.
  • Under the terms of the settlement agreement with Heritage, the company is required to pay $10 million to be used for restitution and costs. According to the AGs, Apotex is required to pay $39 million. Both companies must also cooperate in ongoing litigation against other companies.
  • We have previously reported on Mississippi AG Lynn Finch's settlement with Teva Pharmaceuticals USA, Inc. to resolve similar claims.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More